Clinical Trial Update: Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma [Phase 2]

View source ↗

Summary

Phase II trial of nivolumab plus ramucirumab in previously treated malignant mesothelioma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Ramucirumab (Cyramza) (ramucirumab)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Arkadiusz Z. Dudek, MD | Conditions: Mesothelioma, Malignant | Phase 2 | Status: TERMINATED | Results posted: 2023-10-26